Based on the literature implicating VEGFR3 in metastatic spread in murine breast cancer models, its specificity for lymphatics, as well as the potential connection to VEGFR3 as seen in our gene set enrichment analysis (Figure 1J), we hypothesized that blockade of VEGFR3 would abrogate the effects of carboplatin on lymphatics. Here, FLT4 is linked to breast carcinoma.